Dr. Salha Bujassoum Al Bader
Medical Oncologist/Hematologist
Chairperson of Medical Oncology and Palliative Care Medicine
Associate Professor -Qatar University -Medical College
Clinical Faculty for Master of Genetic Counselling -Qatar University
National Center for Cancer Care and Research
Hamad Medical Corporation, Doha, Qatar
Dr. Salha Bujassoum Al-Bader is a Senior Consultant, Medical Oncology at the National Centre for Cancer Care & Research, a Chairperson of Medical Oncology and Palliative Care Medicine, and the Director of Cancer Genetics Program Hamad Medical Corporation. She has also been the Clinical Lead of Breast Cancer Program since 2005, the Lead of National Clinical Advisory Board of Qatar Breast Cancer, and Assistant Chair of HMC - Precision Medicine Committee.
She obtained a Bachelor of Medicine and Bachelor of Surgery from King Saud University in Riyadh, Saudi Arabia, in 1992. She finished her Postgraduate studies in Canada and received the Specialist Certificate in Internal Medicine/Hematology from the Royal College of Physicians and Surgeons of Canada, Toronto-Canada, in 2000. She was certified by the American Board of Internal Medicine/Clinical Hematology and Medical Oncology, Toronto, Canada, in 2000, 2001, and 2004.
Dr. Salha Bujassoum was appointed as Consultant in Haematology/Oncology in Hamad General Hospital from February 2003 to 2005 and then was promoted as Sr. Consultant in Hematology/Oncology in NCCCR in 2005. She is a member of several international oncology societies such as ESMO, ASCO, and the International Agency for Research on Cancer (IARC) Scientific Council. Her research activities focused on breast and gynecological malignancy and cancer genetics. She has multiple active grants from QNRF, and has been the author of several publications and guidelines. She established various services unique to the cancer program; one is the ACGME-I Accredited Medical Oncology Fellowship. She is the founder of the Breast Tumour Board in 2005, the founder of Hospital-based standard risk breast cancer screening in 2008, and the founder of the Hereditary Cancer Genetic Program in 2013.
In recognition of her effort in improving patient care, she received six stars of excellence awards in the last three consecutive years.
